Subject: Pain Management (Page 1 of 7)
|
|
- Gloria Joseph
- 10 months ago
- Views:
Transcription
1 Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all patients have the right to adequate pain assessment including documentation of the location, intensity, quality, onset, duration, effects of, and exacerbating factors. It is the intent of this pain management policy to define guidelines for management of both Acute and Chronic Non-Cancer Pain. The objectives are as follows: I. To ensure members with chronic non-cancer pain are treated with respect and dignity according to the same basic principles as other chronic illnesses. II. To ensure that members with Acute or Chronic Non-Cancer Pain receive appropriate, timely, and optimal assessment of their pain with a treatment plan, which includes assessment tools and regular follow-up assessments. III. To ensure that the pain assessment includes all aspects of the member s functioning, including physical, psychological, social and work-related factors. IV. To ensure that all Providers and Clinical Office Staff are properly educated on Pain Management Rules and Guidelines set by the State of Oregon. V. To Adapt and Follow the Healthy Columbia Willamette Coalition (HCWC) Standard for New Opioid Prescriptions for Patients with Chronic Non-Cancer/Non-Terminal Pain. Definitions: I. Acute Pain is a type of pain that is directly related to tissue injury. It is of short duration, 3 months or less, and gradually resolves as the injured tissues heal. Examples of Acute Pain are Surgery, an Injury such as a Fracture, Tear, or Laceration, or an Infection or Inflammatory Process. II. Chronic Non-Cancer Pain is a type of pain that extends beyond the expected duration of healing, or 3 months. Chronic Pain is defined as persistent and can be either continuous or recurrent, and of sufficient duration and intensity
2 Subject: Pain Management (Page 2 of 7) to adversely affect the patient s well-being, level of function, and quality of life. There are four types of chronic non-cancer pain. These types are: A. Neuropathic Pain. This is pain produced by damage or dysfunction of the nervous system. Examples of Neuropathic Pain are: 1. Sciatica Diabetic Neuropathy 2. Trigeminal Neuralgia 3. Post Herpetic Neuralgia B. Muscle Pain. This is the most common form of pain and may be due to: 1. Muscle Strain 2. Direct Trauma 3. Vascular Insufficiency 4. Fibromyalgia 5. Myofascial Pain Syndromes C. Inflammatory Pain. Pain that is caused by inflammatory chemicals that directly stimulates primary nerves that carry pain information. Examples of Inflammatory Pain are: 1. Arthritis 2. Infection 3. Tissue Injury 4. Post-operative Pain D. Mechanical/Compressive Pain. Pain that is caused by mechanical pressure or stretching that directly stimulates the pain sensitive neuron. Examples of Mechanical/Compressive Pain are: 1. Neck and Back Pain 2. Degeneration of Disks or Facets 3. Fractures and Obstruction 4. Dislocation or Compression of Tissue III. A Consultation is an evaluation of a patient by a specialist in a related anatomic or pain discipline with recommended treatment options and then the patient returns to the primary care physician for implementation (ICSI, 2005). IV. A Referral is where the patient is being sent to the specialist for not only evaluation, but also ongoing care with little or no long term involvement by the
3 Subject: Pain Management (Page 3 of 7) primary care or referring physician (if different from primary care) (ICSI, 2005). V. To ensure that education of members, their families and Providers is carried out in a culturally competent manner. In 2014, the Patient Safety Subcommittee of the American Academy of Neurology requested a review of the science and policy issues regarding the rapidly emerging public health epidemic of prescription opioid-related morbidity and mortality in the United States. Over 100,000 persons have died, directly or indirectly, from prescribed opioids in the United States since policies changed in the late 1990 s. In the highest-risk group (age years), these deaths have exceeded mortality from both firearms and motor vehicle accidents. While there is evidence for significant short-term pain relief with opioids, there is no substantial evidence for maintenance pain relief or improved function over long periods of time without incurring serious risk of overdose, dependence, or addiction. Fifty percent of patients taking opioids for at least 3 months are still on opioids 5 years later. Policy: I. (THA) members will have access to appropriate and effective pain management. The treatment plan will be based on the following: A. Type of Pain (Acute or Chronic Non-Cancer Pain) B. Onset of Pain C. Intensity of Pain D. Current and/or past treatments for the pain, if any E. Underlying or Co-Existing Disease Processes F. Effect of the Pain on Physical and Psychological Function G. History of Substance Abuse H. History of Mental Illness I. Current Medication List II. For members with Acute Pain resulting from injury or surgery, the goal is Adequate Analgesia, but should be time limited. Opiates should be prescribed with great caution in the context of substance abuse. Opioid dosages above 120
4 Subject: Pain Management (Page 4 of 7) MED/day are not permitted. The concomitant use of Benzodiazepines and Opioids is inadvisable due to the synergistic effect of those drugs, resulting in respiratory depression. Experienced Clinicians can judge the average length of time that an acute injury should require opioids, and a step-down approach to Non- Opioid Analgesics is recommended after that time. III. Providers Prescribing Opioids for Intractable or Chronic Non-Cancer Pain should be treated according to Oregon Revised Statutes (ORS), and the Oregon Administrative Rules (OAR) IV. According to the above mentioned rules and regulations: A. Acute pain treatment will be time limited, 3 months or less, with Opioid Dosages not to exceed 120 MED/day. Concomitant use of Benzodiazepines is inadvisable. B. Acute Musculoskeletal Pain should be treated conservatively with Physical Therapy and Conditioning, Heat, Ice, Good Sleep Hygiene, Good Nutrition, Weight Loss, or Pool Therapy. If these measures are ineffective, introduction of NSAIDS or Acetaminophen can be explored. Skeletal Muscle Relaxants should be a last resort, and utilized acutely after an injury and discontinued thereafter. C. Chronic Non-Cancer Pain Management with a patient already taking daily Opioids should follow these guidelines: 1. Previous patient records should be evaluated before prescribing. Perform Alcohol and Drug Use Screen to identify use disorders and confirm medications are not being diverted. 2. A PDMP Report should be created prior to each office visit and included in the medical record. 3. An initial Urine Drug Screen should be performed, and randomly thereafter to evaluate for illicit substances or opioids not currently prescribed. 4. If Opioids are to be continued, a THA Pain Management Contract will be initiated. Copies of this signed agreement will be kept in the patient s Provider file, THA Case Management File, and on the ED Care Plan. If the member violates this Contract, the authorization for further Opioids will immediately end.
5 Subject: Pain Management (Page 5 of 7) 5. Weekly appointments are encouraged to evaluate compliance, effectiveness and safety. 6. Concomitant use of Alcohol, Benzodiazepines, Sedative-Hypnotics, and Marijuana should be avoided. 7. For members receiving dosages higher than 120 MED/day, a Tapering Protocol must be initiated. The MED Dose Equivalency table should be used as a guide for dosing. OPIOID Morphine Codeine Hydrocodone Hydromorphone Methadone Oxycodone Oxymorphone Fentanyl Transdermal APPROX. EQUIV. DOSE 30mg 200mg 30mg 7.5mg Chronic: 4mg 20mg 10mg 12.5mcg/hr Slow-Taper Protocol: 1. Long-acting opioids: Decrease total daily dose by 5-10% of initial dose per week. 2. Short-acting opioids: Decrease total daily dose by 5-15% per week. 3. Once 25-50% of the total dose is reached, the rate of taper can be slowed to 5% per week. 4. Patient should have weekly appointments, and aberrant behaviors should be addressed by referral to a behavioral health specialist as soon as possible to assure patient compliance and safety. 5. Consider use of adjuvants for management of withdrawal symptoms: a. Antidepressants to manage irritability and/or sleep disturbances b. Hydroxazine for insomnia and anxiety c. Anti-epileptics for neuropathic pain d. Clonidine for autonomic withdrawal symptoms
6 Subject: Pain Management (Page 6 of 7) e. NSAIDS for myalgia f. Anti-diarrheal agents for diarrhea D. Consider a Slow-Taper Method for patients currently taking Benzodiazepines after achieving a reduced baseline dose of Opioids. E. Encourage patient participation in Individual and/or Group Substance Abuse Therapy. F. Chronic Musculoskeletal Pain should be managed with Physical Therapy and Conditioning, Heat, Ice, Good Sleep Hygiene, Good Nutrition, Weight Loss, and Pool Therapy. Opioid pain medications are not appropriate treatment or the standard of care to chronic musculoskeletal pain. NSAIDS and muscle relaxants should be used sparingly and only in cases of flareups or concurrent pain conditions. G. All Opioids will require Prior Authorization by THA Case Management. Patients receiving Opioids and have a signed Pain Contract on file will be monitored for compliance. Any violation of the Pain Contract will result in a block being placed in the pharmacy system for any further refills or new Opioid Prescriptions. H. Consider a transition to Buprenorphine from a Credentialed Physician, with weekly visits to a Buprenorphine Clinic. V. Coordination of Care A. The Primary Care Physician will be responsible for coordinating referrals/consultations with specialists to address the pain or its underlying cause. B. The Primary Care Physician s office will be encouraged to contact the THA Case Management Department if assistance is needed. C. A Prior Authorization is required for all referrals to a Pain Management Clinic. 1. Supportive Documentation must accompany the referral request, including need for referral and thorough Pain Assessment. 2. THA Pain Contract must be signed by the patient and Physician and accompany the referral request if the patient is currently receiving opioids. 3. A Current PDMP Report must accompany referral request. D. Members desiring to enter a Detoxification program should be referred to Hooper Detoxification Stabilization Center of Portland. Subject: Pain Management (Page 7 of 7)
7 1. Members or Primary Care Physicians should call Hooper for specific admission information. 2. THA Case Management will have active participation with all members admitted to Hooper, supporting after-care needs via the Community Outreach Specialists. a. Member success will be reinforced by Case Management with regular phone communication and meeting members at provider appointments when available. b. Community Resources will be provided to members upon request, including Behavioral Health Provider information. References: Healthy Columbia Willamette Coalition (HCWC); Opioids for Chronic Non-cancer Pain: A Position Paper of the American Academy of Neurology; Oregon Pain Guidance Opioid Prescribing Guidelines 2015; Medical Review Institute of America, Anesthesiology and Pain Medicine Review; Oregon Health Authority Mel Kohn, MD MPH. Formulated: August 2003 Reviewed: April 2015 August 2017 Revised June 2007 December 2009 June 2012 April 2015
I. Chronic Pain Information Page 2-3. II. The Role of the Primary Care Physician in Chronic Pain Management Page 3-4
SUTTER MEDICAL FOUNDATION (SMF) 2750 GATEWAY OAKS DRIVE, #150 SACRAMENTO, CA 95833 SPA PCP Treatment & Referral Guidelines PAIN MANAGEMENT Developed June 1, 2003 Revised (Format Revisions) November 13,
Opioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
Tapering Opioids Best Practices*
Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand
Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR
Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful
Recommendations in Opioid Prescribing Guidelines for Chronic Pain
Recommendations in Opioid Prescribing Guidelines for Chronic Pain The use of opioids for treating chronic pain has been increasing. 1 In 2010, an estimated 20% of patients presenting to physician offices
Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline
Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months
Shining a Light on MEDs Understanding morphine equivalent dose
Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
Opiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
Opioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
IEHP UM Subcommittee Approved Authorization Guidelines Referrals to Pain Management Specialists
IEHP Policy: Based on a review of the currently available literature and community standards of practice, the IEHP UM Subcommittee will consider referrals to Pain Management Specialists medically necessary
Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA
Department of Veterans Affairs Network Policy No.: 2014-01 VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA CHRONIC OPIOID USE FOR NON-MALIGNANT PAIN 1. PURPOSE: To
Safe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
Vermont. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of
Opioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older
Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Summary This quality standard provides guidance on the appropriate prescribing, monitoring, and tapering of opioids to treat
TAPMI physicians and nurse practitioners will not take over prescribing permanently.
Please fax all five pages of the referral form together with requested imaging and consult notes to Toronto Academic Pain Medicine Institute (TAPMI) Central Intake at 416-323-2666. Your patient s referral
KANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998
KANSAS Kansas State Board of Healing Arts Source: Kansas State Board of Healing Arts Approved: October 17, 1998 GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF PAIN Section 1: Preamble
EXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
IEHP UM Subcommittee Approved Authorization Guidelines Referrals to Pain Management Specialists
IEHP Policy: Based on a review of the currently available literature and community standards of practice, the IEHP UM Subcommittee will consider referrals to Pain Management Specialists medically necessary
Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina
Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Robert B. Hanlin, M.D., FAAFP Vice Chair, Medical Staff Affairs Greenville Health System Greenville, SC Disclosures
Revised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
Medications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant
Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant South College School of Pharmacy Knoxville, TN (304) 546-7746
Legal Issues in Opioid Prescribing
Legal Issues in Opioid Prescribing Joanne L. Martin, J.D. Legal Counsel Mayo Clinic Rochester, Mn 2015 MFMER slide-1 Conflict of Interest I have no relevant financial relationships to disclose I will not
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
Assessment and Treatment of Chronic, Non-malignant Pain. Jill Chaplin, MD
Assessment and Treatment of Chronic, Non-malignant Pain Jill Chaplin, MD I have nothing to disclose I work for Peace Health Medical Group, and will share some of our processes, but have no commercial interest
Best Practices in Prescribing Opioids for Chronic Non-cancer Pain
Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G
Opiate Use among Ohio Medicaid Recipients
Opiate Use among Ohio Medicaid Recipients July 12, 2012 Ohio Colleges of Medicine Government Resource Center The Ohio State University College of Public Health Sponsored by The Ohio Department of Alcohol
Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain
Substances for the Treatment of Pain Effective January 2007, the Board of Healing Arts appointed a Task Force to review the current statutes, rules and guidelines regarding the treatment of pain. This
Soma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.07 Subject: Soma Page: 1 of 7 Last Review Date: September 15, 2017 Soma Description Soma (carisoprodol),
Chronic Pain, Opioids, & Addiction: Assessing and Managing Risk
Chronic Pain, Opioids, & Addiction: Assessing and Managing Risk Randy Brown MD, PhD, FASAM Associate Professor, Dept of Family Medicine Director, Center for Addictive Disorders, UWHC Director, UW Addiction
Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults
SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults BACKGROUND The justification for developing these guidelines lies
Opioid Task Force Kick-Off Meeting. February 29, 2016
Opioid Task Force Kick-Off Meeting February 29, 2016 Scope of the Opioid Problem and Data Review Olivia Kasirye, MD, MS County Public Health Officer OVERVIEW The Opioid Epidemic Opioid Task Force Development
Analgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
Prepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
Disclosures. Management of Chronic Pain for Cancer Survivors. University of Kentucky HealthCare, Lexington, KY
Management of Chronic Pain for Cancer Survivors Paul A. Sloan, M.D. Professor and Vice Chair for Research Associate Program Director, Pain Medicine Fellowship Department of Anesthesiology University of
Chronic Pain Management in the Primary Care Setting
Chronic Pain Management in the Primary Care Setting Keeping you and your patients safe. Joel Porter, MD October 1, 2015 Chronic Pain Management Chronic pain is a major public health problem Existing chronic
3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
Disclosures. Objectives 9/8/2015
The Aftermath of the Decade of Pain: Alternatives to Opioids in Chronic Pain Management Julie Cunningham, PharmD, BCPP Disclosures No relevant financial disclosures I will discuss off-label uses of antiepileptics,
Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent
MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent Pain may be effectively managed through the use of controlled substance medications (referred to below as opioids
Introduction to the NC ED Pain Management Guidelines. April 12, 2017
Introduction to the NC ED Pain Management Guidelines April 12, 2017 Our Agenda Overview of Opioid Epidemic Our Committee Efforts Review of NC ED Pain Management Guidelines NCHA Grant Overview 2 Polling
Chronic Pain in Patients With HIV: What Clinicians Need to Know
Chronic Pain in Patients With HIV: What Clinicians Need to Know Jessica S. Merlin, MD, MBA Assistant Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FLOWED: 11/03/2015 Learning
OPIOID PAIN MEDICATION Agreement and Informed Consent
OPIOID PAIN MEDICATION Agreement and Informed Consent I. Introduction Research and clinical experience show that opioid (narcotic) pain medications are helpful for some patients with chronic pain. The
OPIOID PRESCRIBING RULES. May 17, 2017 Webinar
OPIOID PRESCRIBING RULES May 17, 2017 Webinar Outline Introduction and Universal Precautions Dr. Levine, Commissioner, Health Department 15 Minutes Acute Pain Dr. Patti Fisher, UVMMC 20 Minutes Chronic
Opioid Overdose Best Practices Guideline. Table of Contents. A. General description: B: Typical signs and symptoms:
Opioid Overdose Best Practices Guideline Table of Contents A. General description B. Typical signs and symptoms C. Expected course D. Making the diagnosis E. Recommended treatment F. Criteria for hospital
``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts
Opioids Effective Case Management Opioids RELEVANCE IN WORKERS COMP Opioids are a diverse group of drugs that represent the strongest pain medications available. They are frequently prescribed for pain
West Virginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile West Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
Prescription for Disaster: Impact of Drugs in our Society
Prescription for Disaster: Impact of Drugs in our Society What you can do about the epidemic of drug abuse in our communities 1 Florida Poison Information Center-Tampa 10/26/2012 Cynthia R. Lewis-Younger,
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
Overview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
Opioid Prescribing: Avoiding Pitfalls and Employing Safe Strategies. Essentials in Pain Management: Update 2017 Michael Weinberger MD
Opioid Prescribing: Avoiding Pitfalls and Employing Safe Strategies Essentials in Pain Management: Update 2017 Michael Weinberger MD The Problem 2015 52,404 2016 64,070 20% increase The Problem Drug
Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain
Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain Department of Veterans Affairs (VA) and Department of Defense
Dr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force
Dr. Smith Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force 1 1 How We Got Here 2 The Epidemic 3 4 San Diego Death Diaries
IEHP Pain Management Clinical Practice Guideline
IEHP Pain Management Clinical Practice Guideline (Last Updated February 2017) Table of Contents 1. Patient Evaluation and Risk Stratification 2. Informed Consent and Opioid Management Plans 3. Initiating
Methadone Treatment. in federal prison
INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional
Morphine equivalent calculator suboxone
Morphine equivalent calculator suboxone Gogamz Menu Best Way To Lose 30 Pounds In 6 Months Fat Burner Waist Belt Fat Burn And Target Heart Rate how much weight would i lose calculator Fastest Fat Burner
Duragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
Disclosures. Get Your Specimens in Order:
Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Jennifer Bolen, JD Disclosures Jennifer Bolen, JD Consultant to Generation Partners Consultant to Abbott
Best Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center
Best Practices in Prescribing Benzodiazepines Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Objectives To review current practice guidelines in benzodiazepine prescribing
Prescription Opioids
What are prescription opioids? Prescription Opioids Opioids are a class of drugs naturally found in the opium poppy plant. Some prescription opioids are made from the plant directly, and others are made
CODE OF RHODE ISLAND RULES
CODE OF RHODE ISLAND RULES AGENCY 14. DEPARTMENT OF HEALTH SUB-AGENCY 060. FOOD AND DRUG CONTROL CHAPTER 009. PAIN MANAGEMENT, OPIOID USE AND THE REGISTRATION OF DISTRIBUTORS OF CONTROLLED SUBSTANCES CRIR
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
Tips for Pain Management
Tips for Pain Management Going for the 3 Increases: Increase in Health, Increase in Happiness & Increase in Energy Strategies for Success in Health Management By: James J. Messina, Ph.D. What are the medical
FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
Neuropathic Pain and Pain Management Options. Mihnea Dumitrescu, MD
Neuropathic Pain and Pain Management Options Mihnea Dumitrescu, MD www.austinppc.com International Association for the Study of Pain (IASP): Definition of Pain Pain is an unpleasant sensory and emotional
The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018
The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology
Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard
Opioid Use in Pregnant Women and Prenatal Care Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Objectives Summarize contextual and co-morbid factors observed among
Drug Class Review. Long-Acting Opioid Analgesics
Drug Class Review Long-Acting Opioid Analgesics Final Update 5 Report April 2008 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
Conflict of Interest Disclosure
Patient Rx Drug Misuse and Abuse: Compliance Toxicology Monitoring in Clinical Practice Toxicology Staff Andrea Terrell, Ph.D., DABCC Chief Scientific Officer George Behonick, Ph.D., DABFT, Manager, FBU
Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
6/6/2017. First Do No Harm SECTION 1 THE OPIOID CRISIS. Implementing an Opioid Stewardship Program in a HealthCare System OBJECTIVES
First Do No Harm Implementing an Opioid Stewardship Program in a HealthCare System Phil Chang, MD Kristy Deep, MD Doug Oyler, PharmD June 12, 2017 OBJECTIVES Explain the role of opioid stewardship as a
15 mg morphine 10 mg hydrocodone
Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
Updated: 08/2017 DMMA Approved: 11/2017
Request for Prior Authorization for Therapy to Treat Binge Eating Disorder Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for medications to treat Binge
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
Chronic Opioid Therapy (COT) Safety Guideline For Patients with Chronic Non-Cancer Pain
Chronic Opioid Therapy (COT) Safety Guideline For Patients with Chronic Non-Cancer Pain Major Changes as of August 2014... 2 Background... 2 Prescribing... 3 Management of Patients on COT... 5 Tapering
Talking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
Pain Management Management in Hepatic Hepatic and and Renal Dysfunction
Pain Management in Hepatic and Renal Dysfunction Review the pharmacologic basis for medications used in pain management Identify pain medications which hshould ldbe avoided in patients with hepatic dysfunction
Opiates & Opioids Opioids
Opiates & Opioids Opioids Opiates Pharmacologic principals important in primary care Present in opium from seedpod of Papaver somniferum Morphine, codeine Opioids Ted Parran MD FACP Are manufactured Isabel
2/21/2018 MYRTLE H GREENE, LMHC,CAP,ICADC INTERVENTION PROJECT FOR NURSES PART 2 OBJECTIVES
PAIN MANAGEMENT IN HEALTH CARE PROFESSIONALS PART 1 MYRTLE H GREENE, LMHC,CAP,ICADC INTERVENTION PROJECT FOR NURSES PART 1 OBJECTIVES Define and identify the characteristics of Chronic Pain Nationwide
: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals
Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals Suzanne A Nesbit, PharmD, CPE Clinical Pharmacy Specialist, Pain Management The Johns Hopkins Hospital Objectives and Disclosures
Objectives. What is pain? 9/27/2017. Pain: Does this Hurt? Fall 2017 Dean Fox, MD, FACP
Pain: Does this Hurt? Fall 2017 Dean Fox, MD, FACP Photo credit: http://multiple-sclerosis-research.blogspot.com/2013/10/pain-and-unemployment.html Objectives Consider personal goal of pain management
Strategies in Managing Opioid and Benzodiazepine Co-Prescribing
Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes
Difficult Conversations
Difficult Conversations D R. L Y D I A A N N E M B A R T H O L O W, D N P, P M H N P, C A R N - AP Skill Building Patient centered Boundaries and self-protection Trauma informed Care 1 Skill Building Trauma
Back in a few minutes Geoff
Back in a few minutes Geoff Conflict of Interest Speaker Name; Dr. Geoff Davis Program Title FINANCIAL DISCLOSURE Grants/Research Support: Archimedes Research Speakers Bureau/Honoraria:Purdue Pharma, Pfizer
Overview of Opioid Use Disorder
Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City Objectives History
Based on Tip 54. Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders KAP KEYS FOR CLINICIANS
Based on Tip 54 Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders KAP KEYS FOR CLINICIANS KAP Keys Based on TIP 54 Introduction KAP Keys were developed to accompany the Treatment
Pain Management Documents
Pain Management Documents Prescriber and Patient Resources Non-cancer Pain Guidance Neuropathic Pain Guidance Stopping or Switching low strength Buprenorphine Patches Red and Yellow Flags Medicines Management
Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good
PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion